Crescent Biopharma, Inc.
CBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1 |
| % Growth | -100% | -86.7% | -93.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $1 |
| % Margin | – | 100% | 100% | 100% |
| R&D Expenses | $56 | $20 | $28 | $47 |
| G&A Expenses | $13 | $19 | $19 | $17 |
| SG&A Expenses | $13 | $19 | $19 | $17 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $69 | $39 | $47 | $65 |
| Operating Income | -$69 | -$39 | -$47 | -$63 |
| % Margin | – | -392,752.9% | -63,204.4% | -5,470.7% |
| Other Income/Exp. Net | -$3 | $2 | $1 | $0 |
| Pre-Tax Income | -$71 | -$37 | -$47 | -$63 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$71 | -$37 | -$47 | -$63 |
| % Margin | – | -368,994.2% | -62,251.7% | -5,469% |
| EPS | -0.59 | -0.58 | -0.89 | -1.23 |
| % Growth | -1.7% | 34.8% | 27.6% | – |
| EPS Diluted | -0.59 | -0.58 | -0.89 | -1.23 |
| Weighted Avg Shares Out | 64 | 63 | 53 | 51 |
| Weighted Avg Shares Out Dil | 64 | 63 | 53 | 51 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $2 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $69 | $0 | $0 | $0 |
| EBITDA | $0 | -$39 | -$47 | -$63 |
| % Margin | – | -391,213.6% | -62,927.6% | -5,447.9% |